NTRA - רווח נקי למניה (EPS TTM) Natera Corp

Demand for genetic diagnostics remains stable even during crises, creating a reliable foundation for growth. Tracking the annual net income per share trend on GURU.Markets, we note that -1.14 shapes the current metric. This is further supported by the explosive success of non-invasive tests and the strategic expansion of the Natera, Inc. (NTRA) portfolio from reproductive medicine to oncology monitoring, which reduces operational risks.

This indicator reflects the actual efficiency of profit generation per ordinary share over a rolling year, allowing for an assessment of the business's ability to convert revenue into net income. For Natera, Inc. (NTRA), this calculation is critical, as the expansion of the genetic testing ecosystem and rising demand must offset FDA regulatory risks, which is clearly reflected in the change in net income per share TTM.